Added to YB: 2026-06-18
Pitch date: 2026-06-16
ADPT [neutral]
Adaptive Biotechnologies Corporation
+47.15%
current return
Author Info
No bio for this author
Company Info
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Market Cap
$3.9B
Pitch Price
$16.84
Price Target
N/A
Dividend
N/A
EV/EBITDA
-569.07
P/E
-58.91
EV/Sales
12.70
Sector
Life Sciences Tools and Services
Category
special_situation
KEDM Lite Vol. 18 - Adaptive Biotechnologies Corporation
ADPT (update): Separating MRD diagnostics & Immune Medicine units, focusing on MRD while exploring strategic/structural options for Immune Medicine; split expected by YE2026. Financing via $250M convertible-notes offering for capped-calls, $25M buybacks, OrbiMed repayment & MRD growth.
Read full article (1 min)